Regulation of tumor antigens-Dependent immunotherapy via the hybrid M1 macrophage/tumor lysates Hydrogel

doi:10.1016/j.heliyon.2024.e37521

科研成果详情

题名	Regulation of tumor antigens-Dependent immunotherapy via the hybrid M1 macrophage/tumor lysates Hydrogel
作者	Li, Zeyang1; Zhan, Jiani 2; Zheng, Yinuo 3; Luo, Yingli 4; Yu, Xiaoming 5; Chen, Haha3
发表日期	2024-09-30
发表期刊	Heliyon 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Tumor immunotherapy M1/M2 macrophages Hybrid hydrogel Antigens presentation
其他关键词	NANOCOMPOSITE HYDROGELS ; CHEMOTHERAPY ; DELIVERY
摘要	Tumor treatment poses a significant obstacle in contemporary healthcare. Using components derived from a patient's own cellular and tissue materials to prepare hydrogels and other therapeutic systems has become a novel therapeutic approach, drawing considerable interest for their applicability in basic research on cancer immunotherapy. These hydrogels can engage with cellular components directly and offer a supportive scaffold, aiding in the normalization of tumor tissues. Additionally, their superior capability for encapsulating targeted anti-tumor medications amplifies treatment effectiveness. Given their origin from a patient's own cells, these hydrogels circumvent the risks of immune rejection by the body and severe side effects typically associated with foreign substance. In this study, we developed a composite hydrogel constructed by the cellular lysates of autologous tumor cells and M1 macrophages. This combination promoted the M2 macrophages polarization to the M1 phenotype. Subsequently, the polarized M1 macrophages infiltrated into the hydrogel and can directly capture tumor antigens. As antigen-presenting cells, M1 macrophages can stimulate the production of antigen-specific T cells to kill tumor cells. This work proposes a dual-benefit research strategy that not only polarizes M2 macrophages but also enhances immune activation, boosting T cell-mediated tumor-killing effects. This approach offers a new therapeutic option for clinical cancer immunotherapy.
出版者	CELL PRESS
ISSN	2405-8440
EISSN	2405-8440
卷号	10 期号:18
DOI	10.1016/j.heliyon.2024.e37521
页数	7
WOS类目	Multidisciplinary Sciences
WOS研究方向	Science & Technology - Other Topics
WOS记录号	WOS:001313455700001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	39309839
SCOPUSEID	2-s2.0-85203413994
通讯作者地址	[Chen, Haha]Wenzhou Med Univ, Ruian Peoples Hosp, Affiliated Hosp 3, Dept Thyroid & Breast Surg, Wenzhou 325200, Zhejiang, Peoples R China. ; [Luo, Yingli]Jiangnan Univ, Wuxi Sch Med, Wuxi 214122, Jiangsu, Peoples R China. ; [Yu, Xiaoming]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Canc Ctr,Dept Pulm & Crit Care Med, Hangzhou 310014, Zhejiang, Peoples R China.
Scopus学科分类	Multidisciplinary
SCOPUS_ID	SCOPUS_ID:85203413994
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/218626
专题	附属第一医院_超声影像科第一临床医学院（信息与工程学院）、附属第一医院其他_附属第三医院（瑞安市人民医院）
通讯作者	Luo, Yingli; Yu, Xiaoming; Chen, Haha
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Ultrason Imaging, Wenzhou 325000, Zhejiang, Peoples R China; 2.Wenzhou Med Univ, Sch Med 1, Sch Informat & Engn, Wenzhou 325000, Zhejiang, Peoples R China; 3.Wenzhou Med Univ, Ruian Peoples Hosp, Affiliated Hosp 3, Dept Thyroid & Breast Surg, Wenzhou 325200, Zhejiang, Peoples R China; 4.Jiangnan Univ, Wuxi Sch Med, Wuxi 214122, Jiangsu, Peoples R China; 5.Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Canc Ctr,Dept Pulm & Crit Care Med, Hangzhou 310014, Zhejiang, Peoples R China
第一作者单位	附属第一医院_超声影像科
通讯作者单位	其他_附属第三医院（瑞安市人民医院）
第一作者的第一单位	附属第一医院_超声影像科
推荐引用方式 GB/T 7714	Li, Zeyang,Zhan, Jiani,Zheng, Yinuo,et al. Regulation of tumor antigens-Dependent immunotherapy via the hybrid M1 macrophage/tumor lysates Hydrogel[J]. Heliyon,2024,10(18).
APA	Li, Zeyang, Zhan, Jiani, Zheng, Yinuo, Luo, Yingli, Yu, Xiaoming, & Chen, Haha. (2024). Regulation of tumor antigens-Dependent immunotherapy via the hybrid M1 macrophage/tumor lysates Hydrogel. Heliyon, 10(18).
MLA	Li, Zeyang,et al."Regulation of tumor antigens-Dependent immunotherapy via the hybrid M1 macrophage/tumor lysates Hydrogel".Heliyon 10.18(2024).